SBIR Phase I: Prostate cancer diagnosis with an integrated endorectal MRI and targeted transrectal biopsy

SBIR 第一阶段：利用集成直肠内 MRI 和靶向经直肠活检诊断前列腺癌

• 批准号: 2037190
• 负责人: Robert Duffy DuFresne
• 金额: $ 25.58万
• 依托单位: OmnEcoil Instruments, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-12-15 至 2024-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2037190&HistoricalAwards=false
• 关键词: SBIR; Phase; Prostate; cancer; diagnosis

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to improve detection of prostate cancer, a highly prevalent fatal cancer in men. Approximately one million prostate biopsies are performed annually in the U.S. Unfortunately the standard diagnostic method is imprecise and inefficient. The proposed project will advance a new method that uses Magnetic Resonance Imaging (MRI) to target biopsies for improved detection. This Small Business Innovation Research (SBIR) Phase I project will advance diagnosis of prostate cancer by developing a system that combines an endorectal MRI coil and a multichannel array of transrectal biopsy needle guides and allows for endorectal MRI with in-bore biopsy as a single rapid integrated procedure. The project will advance a procedure that optimally combines endorectal MRI and MRI-targeted biopsy.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小型企业创新研究(SBIR)第一阶段项目的更广泛的影响/商业潜力是改进前列腺癌的检测，前列腺癌是一种在男性中非常普遍的致命癌症。在美国，每年大约有一百万例前列腺活检。不幸的是，标准的诊断方法是不准确和低效的。拟议的项目将推进一种新的方法，使用核磁共振成像(MRI)来定位活检，以改进检测。这个小型企业创新研究(SBIR)第一阶段项目将通过开发一种系统来提高前列腺癌的诊断水平，该系统将直肠内核磁共振线圈和多通道经直肠活检针导向器阵列相结合，并允许将直肠内核磁共振和内径活检术作为单一的快速综合程序。该项目将推进一种最佳结合直肠内核磁共振和核磁共振靶向活组织检查的程序。这一奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。